The company’s innovations have not gone unnoticed. AI Medical Service was featured in 
SONIRE’s approach, which utilizes cavitation to enhance treatment accuracy, has been recognized by the U.S. FDA as a breakthrough device. The company is currently conducting a world-first randomized trial to further validate the efficacy of their technology. As CEO Satoh Tohru notes, the goal is to offer a more effective and safer cancer treatment to patients worldwide.
These Japanese startups are not only advancing medical technology but also providing hope for millions of cancer patients globally. As the world braces for a surge in cancer cases, innovations from companies like AI Medical Service and SONIRE Therapeutics could be pivotal in changing the landscape of cancer treatment.
Adverse Childhood Experiences (ACE) Study: Linking Childhood Trauma to Chronic Diseases in Adulthood
The Adverse Childhood Experiences (ACE) Study, a groundbreaking collaboration between the CDC and Kaiser Permanente, has unveiled a startling connection between childhood trauma and the onset of chronic diseases in adulthood. This landmark study, as detailed in the original article from ACEs Too High, introduces the concept of the ACE score—a metric designed to quantify an individual's risk for developing health issues later in life, akin to a cholesterol score for childhood toxic stress.
